(thirdQuint)Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy.

 This is a multi-center, 2 arm, open-label study; - Arm A: Patients previously treated with a uricolytic agent; - Arm B: Patients not previously treated with a uricolytic agent.

 Patients receive rasburicase for 5 days and begin chemotherapy 4-24 hours after the first dose of rasburicase.

 Patients are followed at 14 and 35 days, at 3 and 6 months and every 6 months thereafter.

.

 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy@highlight

This is an open-label, multi-center study with 2 arms.

 The primary objective is to assess the response to treatment with rasburicase in 2 populations of adult and pediatric patients with lymphoma/leukemia/solid tumor malignancies, those previously treated with a uricolytic agent, and those not previously treated with a uricolytic agent at their first relapse or refractory disease.

